Assessment of hepatic VX2 tumors with combined percutaneous transhepatic lymphosonography and contrast-enhanced ultrasonographic imaging

Figure 1 Liver of a VX₂ tumor-bearing rabbit imaged in the conventional mode before (A), immediately after 18 s (B) and 96 s (C) of injection of 0. 1 mL sonazoid microbubbles/kg. Arrows indicate VX₂ tumor.

Figure 2 Hepatic lymph vessels visualized 36 s (A), 4 min (B), 7 min (C) 18 min (D) after injection of contrast agent and continuously visualized with SonoVue^® during PTL with hyperechoic boundaries of VX2 tumors to liver parenchyma and the tumor.

Figure 3 Videodensitometric measurements of liver normal parenchyma (white), tumor parenchyma (gray) and tumor boundary (black) before and after percutaneous transhepatic injection of contrast agent SonoVue^® into the normal liver parenchyma near the VX₂ tumors during PTL. ^aP < 0.05 vs respective pre-injection values (Dunnett).